Phase 2 Colorectal Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People of Chinese ethnicity aged between 18 and 75 years, male or female
- People who have been diagnosed with colorectal cancer confirmed by a tissue biopsy, with a measurable tumour as assessed by standard imaging criteria
- People whose general physical fitness and ability to carry out daily activities meets a certain level (confirm with trial site)
- People whose doctors estimate they are likely to live for more than 3 months
- People for whom a multidisciplinary medical team has agreed that adding a local chemotherapy approach to their existing cancer treatment plan is appropriate
- People whose blood counts, liver function, kidney function, and heart function all meet specific minimum levels set by the trial (confirm with trial site for exact values)
- Women of childbearing age who have a negative pregnancy test within 7 days before joining, and sexually active participants who agree to use appropriate contraception during the trial and for 8 weeks after the last dose of the study treatment
- People who are in suitable physical condition and willing to undergo a specific procedure involving a tube placed into the colon via a camera examination
- People who are willing to attend regular follow-up appointments and tests as recommended after treatment
- People who agree to have tissue or fluid samples collected and who sign a written consent form
Who may not be able to join:
- People with uncontrolled heart conditions — such as severe heart failure, coronary artery disease, irregular heart rhythms, or unstable circulation — that could pose a significant risk during treatment
- People with active, serious infections (including fungal, viral, or tuberculosis infections, particularly in the digestive tract) that are not well controlled
- People with blood clotting problems or a tendency to bleed, or those taking blood-thinning medications such as warfarin or heparin, unless their clotting levels fall within an acceptable range — low-dose warfarin or low-dose aspirin for prevention may be allowed (confirm with trial site)
- People with a known immune system deficiency, another condition that weakens the immune system, or a history of organ transplantation
- People who have another cancer that is currently growing or being actively treated, except for certain minor skin cancers or early-stage cervical changes that have been adequately treated
- People with other serious health conditions that the treating doctor considers would make participation unsafe or unsuitable
- Women who are currently breastfeeding
- People with a known allergy or intolerance to the study drug or any of its ingredients
- People who have participated in another drug clinical trial within the past four weeks
- People who do not have the legal capacity to consent for themselves
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Faming Zhang, MD, PhD, Department of Microbiota Medicine & Medical Center for Digestive Diseases
Phone: 86-025-58509883
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Objective response rate (according to RECIST1.1, investigator assessment)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.